Emerging Markets Earnings Roundup: GlaxoSmithKline (Part 4)
This article was originally published in PharmAsia News
GlaxoSmithKline CEO Andrew Witty took a question on the China compliance investigation and quickly moved on in an earnings call also thin on emerging market plans. However, the earnings release added a bit of detail on both fronts, including up-to-date details on regulatory aspects outside of China.
You may also be interested in...
Decline in Advair sales to cointinue for several years as the portfolio transitions to new products, which have faced reimbursement challenges.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.